PUBLISHER: IMARC | PRODUCT CODE: 1298705
PUBLISHER: IMARC | PRODUCT CODE: 1298705
Cancer Immunotherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
The global cancer immunotherapy market size reached US$ 106.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 182.0 Billion by 2028, exhibiting a growth rate (CAGR) of 8.8% during 2023-2028. The growing number of cancer cases, favorable government initiatives, and wide availability of medical insurance represent some of the key factors driving the market.
Cancer refers to a disease wherein some of the cells in the body grow uncontrollably and spread across several body parts. It is caused by alcohol or tobacco consumption, an unhealthy diet, air pollution, and physical inactivity. It can lead to severe health problems, such as anxiety, depression, fear of death, pain, stress, and suicidal thoughts among individuals. It can be treated through immunotherapy, which comprises antibodies that bind, and inhibit the function of proteins expressed by cancer cells. Cancer immunotherapy assists in boosting the immune system to detect and destroy abnormal cancer cells among individuals. Besides this, it causes fewer side effects as compared to other treatment options and reduces the chances of occurring cancerous cells. As a result, cancer immunotherapy is widely utilized to treat lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers among individuals across the globe.
Cancer Immunotherapy Market Trends and Drivers:
At present, the increasing number of cancer cases due to the poor balanced diet and consumption of toxic substances among individuals around the world represents one of the major factors influencing the market positively. In addition, the rising awareness about various cancer treatment options among the masses across the globe is contributing to the market growth. Apart from this, the growing utilization of cancer immunotherapies, as they provide prolonged progression-free survival (PFS) and overall survival (OS) compared to anti-tumor therapies, is offering a positive market outlook. Moreover, the wide availability and easy access to medical insurance, along with the increasing healthcare expenditure, is offering lucrative growth opportunities to industry investors. In addition, there is a rise in the demand for treatment solutions with fewer side effects among the masses around the world. This, coupled with the growing adoption of cancer immunotherapies due to the increasing approval for novel immunotherapies, is bolstering the growth of the market. In line with this, governing agencies and non-profit organizations of various countries are encouraging the adoption of cancer immunotherapy by spreading awareness about cancer prevention worldwide is impelling the growth of the market. Furthermore, various technological advancements in cancer treatment therapies to efficiently treat the disease are strengthening the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer immunotherapy market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapy type, application and end user.
Therapy Type Insights:
Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
Others
The report has provided a detailed breakup and analysis of the cancer immunotherapy market based on the therapy type. This includes monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators, and others. According to the report, monoclonal antibodies represented the largest segment.
Application Insights:
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Others
A detailed breakup and analysis of the cancer immunotherapy market based on the application has also been provided in the report. This includes lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. According to the report, lung cancer accounted for the largest market share.
End User Insights:
Hospitals
Cancer Research Centers
Clinics
Others
A detailed breakup and analysis of the cancer immunotherapy market based on the end user has also been provided in the report. This includes hospitals, cancer research centers, clinics, and others. According to the report, hospitals accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy. Some of the factors driving the North America cancer immunotherapy market included the growing number of patients suffering from cancer, rising development of bioinformatic tools, favorable government initiatives, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global cancer immunotherapy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy. Some of the factors driving the North America cancer immunotherapy market included the growing number of patients suffering from cancer, rising development of bioinformatic tools, favorable government initiatives, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global cancer immunotherapy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global cancer immunotherapy market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global cancer immunotherapy market?
- What is the impact of each driver, restraint, and opportunity on the global cancer immunotherapy market?
- What are the key regional markets?
- Which countries represent the most attractive cancer immunotherapy market?
- What is the breakup of the market based on the therapy type?
- Which is the most attractive therapy type in the cancer immunotherapy market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the cancer immunotherapy market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the cancer immunotherapy market?
- What is the competitive structure of the global cancer immunotherapy market?
- Who are the key players/companies in the global cancer immunotherapy market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Cancer Immunotherapy Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Therapy Type
- 6.1 Monoclonal Antibodies
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Cancer Vaccines
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Checkpoint Inhibitors
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Immunomodulators
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Application
- 7.1 Lung Cancer
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Breast Cancer
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Colorectal Cancer
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Melanoma
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Prostate Cancer
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Head and Neck Cancer
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 7.7 Others
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Cancer Research Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Clinics
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Amgen Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 AstraZeneca plc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bayer AG
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Bristol-Myers Squibb Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Eli Lilly and Company
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche AG
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 SWOT Analysis
- 14.3.7 GlaxoSmithKline Plc
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Johnson & Johnson
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Merck KGAA
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Novartis AG
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Pfizer Inc.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Sanofi
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.13 Seagen Inc.
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio
- 14.3.13.3 Financials
- 14.3.13.4 SWOT Analysis
- 14.3.1 Amgen Inc.
List of Figures
- Figure 1: Global: Cancer Immunotherapy Market: Major Drivers and Challenges
- Figure 2: Global: Cancer Immunotherapy Market: Sales Value (in Billion US$), 2017-2022
- Figure 3: Global: Cancer Immunotherapy Market Forecast: Sales Value (in Billion US$), 2023-2028
- Figure 4: Global: Cancer Immunotherapy Market: Breakup by Therapy Type (in %), 2022
- Figure 5: Global: Cancer Immunotherapy Market: Breakup by Application (in %), 2022
- Figure 6: Global: Cancer Immunotherapy Market: Breakup by End User (in %), 2022
- Figure 7: Global: Cancer Immunotherapy Market: Breakup by Region (in %), 2022
- Figure 8: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 9: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 10: Global: Cancer Immunotherapy (Cancer Vaccines) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 11: Global: Cancer Immunotherapy (Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 12: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 13: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 14: Global: Cancer Immunotherapy (Immunomodulators) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 15: Global: Cancer Immunotherapy (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 16: Global: Cancer Immunotherapy (Other Therapy Types) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 17: Global: Cancer Immunotherapy (Other Therapy Types) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 18: Global: Cancer Immunotherapy (Lung Cancer) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 19: Global: Cancer Immunotherapy (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 20: Global: Cancer Immunotherapy (Breast Cancer) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 21: Global: Cancer Immunotherapy (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 22: Global: Cancer Immunotherapy (Colorectal Cancer) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 23: Global: Cancer Immunotherapy (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 24: Global: Cancer Immunotherapy (Melanoma) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 25: Global: Cancer Immunotherapy (Melanoma) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 26: Global: Cancer Immunotherapy (Prostate Cancer) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 27: Global: Cancer Immunotherapy (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 28: Global: Cancer Immunotherapy (Head and Neck Cancer) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 29: Global: Cancer Immunotherapy (Head and Neck Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 30: Global: Cancer Immunotherapy (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 31: Global: Cancer Immunotherapy (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 32: Global: Cancer Immunotherapy (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 33: Global: Cancer Immunotherapy (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 34: Global: Cancer Immunotherapy (Cancer Research Centers) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 35: Global: Cancer Immunotherapy (Cancer Research Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 36: Global: Cancer Immunotherapy (Clinics) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 37: Global: Cancer Immunotherapy (Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 38: Global: Cancer Immunotherapy (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 39: Global: Cancer Immunotherapy (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 40: North America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 41: North America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 42: United States: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 43: United States: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 44: Canada: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 45: Canada: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 46: Asia-Pacific: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 47: Asia-Pacific: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 48: China: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 49: China: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 50: Japan: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 51: Japan: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 52: India: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 53: India: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 54: South Korea: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 55: South Korea: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 56: Australia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 57: Australia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 58: Indonesia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 59: Indonesia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 60: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 61: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 62: Europe: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 63: Europe: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 64: Germany: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 65: Germany: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 66: France: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 67: France: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 68: United Kingdom: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 69: United Kingdom: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 70: Italy: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 71: Italy: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 72: Spain: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 73: Spain: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 74: Russia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 75: Russia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 76: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 77: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 78: Latin America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 79: Latin America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 80: Brazil: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 81: Brazil: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 82: Mexico: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 83: Mexico: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 84: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 85: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 86: Middle East and Africa: Cancer Immunotherapy Market: Sales Value (in Million US$), 2017 & 2022
- Figure 87: Middle East and Africa: Cancer Immunotherapy Market: Breakup by Country (in %), 2022
- Figure 88: Middle East and Africa: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 89: Global: Cancer Immunotherapy Industry: SWOT Analysis
- Figure 90: Global: Cancer Immunotherapy Industry: Value Chain Analysis
- Figure 91: Global: Cancer Immunotherapy Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Cancer Immunotherapy Market: Key Industry Highlights, 2022 and 2028
- Table 2: Global: Cancer Immunotherapy Market Forecast: Breakup by Therapy Type (in Million US$), 2023-2028
- Table 3: Global: Cancer Immunotherapy Market Forecast: Breakup by Application (in Million US$), 2023-2028
- Table 4: Global: Cancer Immunotherapy Market Forecast: Breakup by End User (in Million US$), 2023-2028
- Table 5: Global: Cancer Immunotherapy Market Forecast: Breakup by Region (in Million US$), 2023-2028
- Table 6: Global: Cancer Immunotherapy Market: Competitive Structure
- Table 7: Global: Cancer Immunotherapy Market: Key Players
